Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | BAD | Q92934 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152117 | 1.00 | TSHR (0.46) | TSHRBCL2L1BADCYP2A6MAOA | |
| SCHEMBL151022 | 1.00 | TSHR (0.46) | TSHRBCL2L1BADCYP2A6MAOA | |
| SCHEMBL8890 | 0.98 | TSHR (0.48) | TSHRBCL2L1BADCYP2A6MAOA | |
| SCHEMBL24682 | 0.93 | — | — | |
| SCHEMBL34907 | 0.83 | — | — | |
| SCHEMBL2885325 | 0.76 | TSHR (0.50) | TSHRBCL2L1BADCYP2A6MAOA | |
| SCHEMBL10471250 | 0.75 | CYP2A6 (0.47) | TSHRCYP2A6MAOAMAOBHPGD | |
| SCHEMBL520050 | 0.74 | — | — | |
| SCHEMBL12520890 | 0.72 | TSHR (0.31) | TSHR | |
| SCHEMBL5420509 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156778-A1 | THIOPHENE DERIVATIVES FOR USE IN TREATING PORTAL INFLAMMATION AND FIBROSIS | ENYO PHARMA (FR) | 2024-05-16 | — | — | US | claimed |
| US-20230339958-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230331753-A1 | Ligand Compound, Organochromium Compound and Catalyst System Comprising the Same | LG CHEM, LTD. (KR) | 2023-10-19 | — | — | US | claimed |
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | ENYO PHARMA (FR) | 2023-10-12 | — | — | US | claimed |
| EP-4215537-A1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND, AND CATALYST SYSTEM COMPRISING SAME | Lg Chem, Ltd. (KR) | 2023-07-26 | — | — | EP | claimed |
| EP-4196482-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | claimed |
| EP-4192448-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | ENYO Pharma (FR) | 2023-06-14 | — | — | EP | claimed |
| WO-2022036297-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | claimed |
| US-20220009938-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2022-01-13 | — | — | US | claimed |
| US-6057352-A | CONTROLLING PLANT DISEASES CAUSED BY FUNGAL PLANT PATHOGENS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | claimed |
| WO-1998033382-A1 | FUNGICIDAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998023155-A1 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0836384-A1 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-04-22 | — | — | EP | claimed |
| EP-0825992-A1 | FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-03-04 | — | — | EP | claimed |
| EP-0821677-A1 | OXAZOLINE AND THIAZOLINE ARTHROPODICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-02-04 | — | — | EP | claimed |
| WO-1997000612-A1 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-01-09 | — | — | WO | claimed |
| WO-1996036229-A1 | FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-11-21 | — | — | WO | claimed |
| WO-1996036633-A1 | FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-11-21 | — | — | WO | claimed |
| WO-1996033180-A1 | OXAZOLINE AND THIAZOLINE ARTHROPODICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-10-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156778-A1 | THIOPHENE DERIVATIVES FOR USE IN TREATING PORTAL INFLAMMATION AND FIBROSIS | FABP1, SLC10A1, TPMT | TSHR 2612/4885BCL2L1 2439/4885BAD 3256/4885 |
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | TSHR 2253/4885BCL2L1 4399/4885BAD 2929/4885 |
| US-20230331753-A1 | Ligand Compound, Organochromium Compound and Catalyst System Comprising the Same | ETV6, ESR1, OXER1 | TSHR 655/4885BCL2L1 1121/4885BAD 1316/4885 |
| US-20230339958-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SCN7A, SCN10A, HCN3 | TSHR 4297/4885BCL2L1 2995/4885BAD 1589/4885 |
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | TST, TPMT, MMP1 | TSHR 2177/4885BCL2L1 3811/4885BAD 2667/4885 |
| US-20220009938-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, SCN3A | TSHR 2772/4885BCL2L1 4009/4885BAD 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.